Red Light Holland Secures Second United States Controlled Substances Import Permit for the Company's Psilocybin Through FDA-Compliant, DEA-Registered Partner Irvine Labs
Red Light Holland (OTCQB: TRUFF) announced that its FDA‑compliant, DEA‑registered partner Irvine Labs received a second United States Controlled Substances import permit on October 14, 2025, authorizing the import equivalent to 5 kg of psilocybin truffles from Red Light Holland's Netherlands facility.
The company said this follows a Certificate of Analysis confirming psilocybin potency and process validation in September 2025 and will support expanded R&D into dehydration, packaging, shelf‑life extension, and standardized microdosing capsule development for potential medical‑grade manufacturing, government pilot programs, and clinical trials.
Red Light Holland (OTCQB: TRUFF) ha annunciato che il suo partner DEA-registrato, conforme FDA, Irvine Labs, ha ricevuto un secondo permesso di importazione di Sostanze Controllate negli Stati Uniti in data 14 ottobre 2025, autorizzando l'importazione equivalente a 5 kg di tartufi alla psilocibina provenienti dall'impianto dei Red Light Holland nei Paesi Bassi.
L'azienda ha dichiarato che ciò segue un Certificate of Analysis che conferma la potenza della psilocibina e la validazione del processo a settembre 2025 e supporterà l'espansione della ricerca e sviluppo in dehydratazione, confezionamento, estensione della shelf-life e sviluppo di capsule microdosaggio standardizzate per potenziali lavorazioni di grado medico, programmi pilota governativi e studi clinici.
Red Light Holland (OTCQB: TRUFF) anunció que su socio registrado por la DEA y conforme a la FDA, Irvine Labs, recibió un segundo permiso de importación de Sustancias Controladas en Estados Unidos el 14 de octubre de 2025, autorizando la importación equivalente a 5 kg de trufas de psilocibina desde la instalación de Red Light Holland en los Países Bajos.
La empresa dijo que esto sigue a un Certificate of Analysis que confirma la potencia de la psilocibina y la validación del proceso en septiembre 2025 y apoyará la expansión de I+D en deshidratación, envasado, prolongación de la vida útil y desarrollo de cápsulas estandarizadas de microdosificación para posibles manufacturas de grado médico, programas piloto gubernamentales y ensayos clínicos.
Red Light Holland (OTCQB: TRUFF)는 FDA 준수, DEA 등록 파트너인 Irvine Labs가 2025년 10월 14일에 미국 내 두 번째 규제물질 수입 허가를 받아, 네덜란드 시설에서 psilocybin 트뤼플 5kg의 수입에 해당하는 허가를 받았다고 발표했다.
회사는 이는 2025년 9월에 확인된 psilocybin 효능 및 공정 검증을 포함하는 Certificate of Analysis에 따른 것이며, 건조화, 포장, 유통기한 연장 및 표준화된 마이크로도징 캡슐 개발 등 의약품 등급 제조, 정부 파일럿 프로그램 및 임상 시험에 대한 연구개발 확대를 지원할 것이라고 말했다.
Red Light Holland (OTCQB: TRUFF) a annoncé que son partenaire enregistré par le DEA et conforme à la FDA, Irvine Labs, a reçu un second permis d'importation de substances contrôlées aux États-Unis le 14 octobre 2025, autorisant l'importation équivalente à 5 kg de truffes à la psilocybine depuis l'installation de Red Light Holland aux Pays-Bas.
La société a indiqué que cela fait suite à un Certificate of Analysis confirmant la puissance de la psilocybine et la validation du procédé en septembre 2025 et soutiendra l'expansion de la R&D dans la désiccation, l'emballage, la prolongation de la durée de vie et le développement de gélules de microdosage standardisées pour une fabrication potentielle de grade médical, des programmes pilotes gouvernementaux et des essais cliniques.
Red Light Holland (OTCQB: TRUFF) gab bekannt, dass sein FDA-konformer, DEA-registrierter Partner Irvine Labs am 14. Oktober 2025 eine zweite Importgenehmigung für kontrollierte Substanzen in den Vereinigten Staaten erhalten hat, die den Import von 5 kg Psilocybin-Trüffeln aus der Niederlassung von Red Light Holland in den Niederlanden erlaubt.
Das Unternehmen sagte, dies folge auf ein Certificate of Analysis, das die Potenz von Psilocybin und die Prozessvalidierung im September 2025 bestätige und die umfassende F&E in Trocknung, Verpackung, Haltbarkeitsverlängerung und der Entwicklung standardisierter Mikrodosierungs-Capsulen für potenzielle medizinische Herstellung, Regierungs-Pilotprogramme und klinische Studien unterstützen werde.
Red Light Holland (OTCQB: TRUFF) أعلنت أن شريكها المسجل لدى DEA والمتوافق مع FDA Irvine Labs قد تلقى تصريج استيراد ثانٍ للمواد الخاضعة للسيطرة في الولايات المتحدة في 14 أكتوبر 2025، يسمح باستيراد يعادل 5 كغ من فطر psilocybin من منشأة Red Light Holland في هولندا.
وقالت الشركة إن ذلك يعقب Certificate of Analysis يؤكد قوة psilocybin واعتماد العملية في سبتمبر 2025 وسيعزز البحث والتطوير الموسع في التجفيف والتعبئة وإطالة العمر الافتراضي وتطوير كبسولات Microdosage موحدة للاستخدام الطبي المحتمل، وبرامج تجريبية حكومية وتجارب سريرية.
Red Light Holland (OTCQB: TRUFF) 宣布，其符合FDA规定、获得DEA注册的合作伙伴 Irvine Labs 在 2025年10月14日 收到第二张美国受控物质进口许可，授权从 Red Light Holland 在荷兰的设施进口相当于 5 千克 psilocybin 松露。
公司表示，这一许可此前紧随 Certificate of Analysis，确认 psilocybin 的效力及在 2025 年 9 月的工艺验证，并将支持在脱水、包装、货架期延长以及标准化微剂量胶囊开发等方面的扩展研究与开发，面向潜在的药用级制造、政府试点项目和临床试验。
- DEA import permit authorizes equivalent of 5 kg psilocybin truffles
- Second permit indicates regulatory progress since September 2025 COA
- COA confirmed psilocybin potency and process validation
- Enables R&D on dehydration, packaging, and shelf‑life extension
- Advances work toward standardized microdosing capsules for trials
- None.
- Red Light Holland granted Second DEA Import Permit through Irvine Labs for expanded psilocybin research program
- This United States Controlled Substances Permit, authorizes a significantly larger shipment of psilocybin truffles, from Red Light Holland's Netherlands facility, for continued R&D
Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announced today that its research and development partner, Irvine Labs Inc., California, USA, has received a second United States Controlled Substances import permit. This latest import permit authorizes a significantly larger shipment of psilocybin truffles for continued research and development activities by their FDA-Compliant, DEA-Registered Lab partner.
The Drug Enforcement Administration issued permit authorizes the import equivalent to 5 kg of psilocybin truffles from Red Light Holland's Netherlands facility. This second import permit represents substantial progress following the successful completion of initial testing and validation work announced in September 2025, which confirmed psilocybin potency and process validation through an official Certificate of Analysis (COA). The increased quantity authorized under this USA controlled substances permit will enable Irvine Labs to advance proprietary dehydration and packaging processes designed to extend shelf life while maintaining product integrity, and to further develop standardized psilocybin products for potential medical grade manufacturing applications.
Red Light Holland and Irvine Labs continue to work collaboratively toward developing processes for the commercial manufacture of microdosing capsules derived from naturally occurring psilocybin truffles, aimed at emerging therapeutic markets, government-funded pilot programs, and clinical trials.
"This second DEA permit marks a significant milestone in our partnership with Irvine Labs and validates the progress we've made in our research and development efforts," said Todd Shapiro, Chief Executive Officer & Director of Red Light Holland. "The increased quantity authorized demonstrates growing confidence in our ability to provide high-quality, naturally derived psilocybin materials suitable for potential medical grade applications, while maintaining full regulatory compliance."
The Company remains committed to legal, responsible access to standardized natural psilocybin products and will continue to provide updates on its overall R&D project as developments warrant.
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.
For additional information on the Company:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlight.co
Website: www.RedLight.co
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events.
The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company's performance, business objectives and milestones and the anticipated timing thereof, and costs in connection with, the execution or achievement of such objectives and milestones, including its plans to continue seeking legal opportunities to increase responsible access to natural psilocybin around the world and Irvine lab's ability to receive a second shipment for development of the Company's psilocybin; the Company and the Company's partners to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the expectations with respect to the Company's development work following the successful testing results of the psilocybin materials delivered to Irvine Labs; the Company's plans for continued development of dehydration and packaging processes by Irvine Labs; the Company's plans for future scheduled imports of psilocybin materials under Irvine Labs' existing 2025 DEA quota; the suitability of the Company's psilocybin materials for medical grade manufacturing applications; the Company's continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs Inc. and the research project to develop a process for the commercial manufacture of microdosing capsules derived from the Company's psilocybin truffles that could be used for medical grade applications; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving further important insights from naturally occurring psilocybin truffles; the Company's ability to extract and expand access to psilocybin products; the Company's ability to sell their product in future legal markets, as currently the company has no control on timing or policy change on future emerging markets, and the Company's ability to scalable production of high-quality, and approved microdosing capsules with extended shelf life via Irvine Labs ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the United States or around the world.
Forward-Looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' abilities, including Irvine Labs to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's ability to realize its plans for Irvine to receive the second shipment for continued psilocybin development work following the successful testing results of the materials delivered to Irvine Labs; the Company's ability to successfully continue to export, development of dehydration and packaging processes through Irvine Labs; the Company's ability to execute future scheduled imports of psilocybin materials under Irvine Labs' existing 2025 DEA quota; the continued suitability of the Company's psilocybin materials for medical grade manufacturing applications; the Company's ability for its continued commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's ability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs and their research project to develop a process for the commercial manufacture of natural-source microdosing capsules derived from the Company's psilocybin truffles that could be used for medical grade applications; the Company proving out potential therapeutic benefits of Psilocybin; the Company receiving important insights from naturally occurring psilocybin truffles; the ability to extract and expand access to psilocybin products; and the Company's ability to have scalable production of high-quality, microdosing capsules with extended shelf life for Global Distribution and The Company's ability to continue shipping products to the United States and eventually the Company's ability to export their manufactured products from the United States to emerging markets, or sell to government funded pilot programs or clinical trials in the US or around the world.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to maintain or exceed its current performance, and carry out its business objectives and milestones and under the anticipated timing and costs in connection with, the execution or achievement of such objectives and milestones; the Company and the Company's partners' inabilities, including Irvine Labs, to maintain its stated licenses and obtain all necessary additional licenses and regulatory approval required for the Company to carry out its plans as described; the Company's inability to realize upon its plans for continued psilocybin development despite the successful testing results; potential issues with ongoing development of dehydration and packaging processes; potential delays or complications with future scheduled imports under the existing DEA quota; changes in the suitability assessment of psilocybin materials for medical grade manufacturing applications; potential issues with future development work; the Company's inability to maintain its commitment towards ensuring legal, responsible access to Red Light's standardized natural psilocybin products; the Company's inability to maintain its commitment to making further announcements with respect to its overall R&D project, including its partnership with Irvine Labs; and The Company's ability to expand and extract access to psilocybin products.
The Company cannot make medical claims and is purely in a R&D phase with its partners Irvine Labs Inc.
Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-Looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270351
FAQ
What did Red Light Holland announce on October 14, 2025 regarding DEA permits for TRUFF?
How does the 5 kg DEA import permit affect Red Light Holland (TRUFF) R&D?
Did Red Light Holland provide analytical proof of potency for TRUFF psilocybin truffles?
Are the imports for commercial sales or research for Red Light Holland (TRUFF)?
What are the next development goals for Red Light Holland after the October 14, 2025 permit?
